Regenerative cellular therapies for neurologic diseases

Lévy, Michaël; Boulis, Nicholas M.; Rao, Mahendra S.; Svendsen, Clive N.

doi:10.1016/j.brainres.2015.06.053

Cited by 31 publications

(26 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the present, there is one trial of mesenchymal stem cells in NMOSD, two trials of neural stem cells in traumatic spinal cord injury, and several trials of mesenchymal stem cells in spinal cord injury that are all in progress [52]. These important studies will shed light on the potential use of stem cells in CNS regeneration that may hopefully be applied in NMOSD in the future.…”

Section: Symptomatic Treatmentmentioning

confidence: 99%

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Kessler

Mealy

Lévy

2015

Curr Treat Options Neurol

Self Cite

131

105

View full text Add to dashboard Cite

Opinion statement Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.

show abstract

Section: Symptomatic Treatmentmentioning

confidence: 99%

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Kessler

Mealy

Lévy

2015

Curr Treat Options Neurol

Self Cite

131

105

View full text Add to dashboard Cite

show abstract

“…[14] First-line agents that have been most effective in treatment of both neuropathic and spastic pain are antiepileptic medications. Gabapentin dosing is usually started at 300 mg three times daily and titrated up, as needed weekly, to a maximum dose of 2400 mg/day.…”

Section: Treatment Of Neuromyelitis Opticamentioning

confidence: 99%

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

et al. 2017

View full text Add to dashboard Cite

Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system with preferential involvement in the optic nerve and spinal cord with a widespread spectrum of clinical features; multiple therapeutic agents have been used with different results. Recent evidence points to B-cell-mediated humoral immunity in the pathogenesis of NMO. Rituximab targets the CD20 antigen on B-cells. Treatment leads to profound B-cell depletion, principally over an antibody-dependent cell cytotoxicity mechanism. The aim of our study was to review clinical trials to elucidate the impact of rituximab on the relapse rate, Expanded Disability Status Scale (EDSS), and progression of disability in NMO. We performed a comprehensive review of all studies that evaluated clinical and paraclinical effects of rituximab on NMO. MEDLINE-PubMed, Web of Sciences, EMBASE, and Cochrane databases up to June 2016 included in our searches. In addition, reference lists from articles identified by search as well as a key review article to identify additional articles included in the study. Rituximab targets the CD20 antigen on B-cells and decreases attack frequency and severity in patients with NMO; however, it does not remove attacks, even when modifying treatment to achieve B-cell depletion. Most of the investigations revealed that EDSS significantly in all patients with rituximab treatment will be decreased after treatment with rituximab. No new or enlarged lesions or pathological gadolinium enhancement was observed in serial brain and spinal cord magnetic resonance imaging, except for those observed concomitantly with clinical relapses and the median length of spinal cord lesions was significantly reduced after therapy. Rituximab targets the CD20 antigen and decreases attack frequency and severity in patients with NMO.

show abstract

“…) and several neurodegenerative diseases (Levy et al . ). Unlike replacement therapies, which require the use of either the pluripotent stem cells themselves or pre‐patterned/pre‐specified cell lineage‐specific precursors, disease modelling and drug screening frequently have the explicit requirement for a population of terminally differentiated cells of the type affected in the disease in question.…”

Section: Introductionmentioning

confidence: 97%

Improving and accelerating the differentiation and functional maturation of human stem cell‐derived neurons: role of extracellular calcium and GABA

Kemp

Rushton

Yarova

et al. 2016

The Journal of Physiology

View full text Add to dashboard Cite

Neurons differentiated from pluripotent stem cells using established neural culture conditions often exhibit functional deficits. Recently, we have developed enhanced media which both synchronize the neurogenesis of pluripotent stem cell-derived neural progenitors and accelerate their functional maturation; together these media are termed SynaptoJuice. This pair of media are pro-synaptogenic and generate authentic, mature synaptic networks of connected forebrain neurons from a variety of induced pluripotent and embryonic stem cell lines. Such enhanced rate and extent of synchronized maturation of pluripotent stem cell-derived neural progenitor cells generates neurons which are characterized by a relatively hyperpolarized resting membrane potential, higher spontaneous and induced action potential activity, enhanced synaptic activity, more complete development of a mature inhibitory GABA receptor phenotype and faster production of electrical network activity when compared to standard differentiation media. This entire process - from pre-patterned neural progenitor to active neuron - takes 3 weeks or less, making it an ideal platform for drug discovery and disease modelling in the fields of human neurodegenerative and neuropsychiatric disorders, such as Huntington's disease, Parkinson's disease, Alzheimer's disease and Schizophrenia.

show abstract

Regenerative cellular therapies for neurologic diseases

Cited by 31 publications

References 68 publications

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

Improving and accelerating the differentiation and functional maturation of human stem cell‐derived neurons: role of extracellular calcium and GABA

Contact Info

Product

Resources

About